Stride Consumer Partners has closed its second fund at a $550 million hard cap, the investment firm confirmed, lifting its assets under management to approximately $1.3 billion and putting fresh capital behind a beauty and personal-care portfolio that already includes Odele, Crown Affair, Skinfix, Patrick Ta and Peachy.

The new vehicle is oversubscribed, according to the firm, a signal that limited partners remain willing to back a mid-market consumer specialist even as broader private-fundraising slows.

Who Stride already backs

Stride's current beauty and wellness roster crosses haircare, skincare, prestige fragrance and medical aesthetics:

• Odele — clean-leaning indie haircare
• Crown Affair — prestige haircare tools and styling
• Skinfix — barrier-focused skincare, frequently stocked in dermatologist and Sephora channels
• Patrick Ta — celebrity-founded prestige colour and skincare
• Peachy — the focused med-spa concept Stride backed to scale its clinic model

The mix reads like a thesis on premiumization: brands that sit at the intersection of clinical credibility, social-first marketing and retail-ready packaging.

What a $550M hard cap means for indie sellers

A second fund of this size, raised on Stride's existing portfolio, points to three things founders, exits and acquirers should track.

First, the check size stretches. With $1.3 billion under management, Stride can write primary rounds and follow-on checks large enough to fund retail expansion, manufacturing scale-up and selective international rollout — the three moves that historically break a bootstrapped indie.

Second, hold periods lengthen. Funds raised against an existing book of performing beauty assets tend to favor bolt-on acquisitions over greenfield bets. Formulators and contract manufacturers should expect a flurry of acquisitions-of-acquisitions — Stride consolidating sku counts inside Skinfix, Odele or Crown Affair — rather than ten new brand launches.

Third, the med-spa arm gets ammunition. Peachy operates a focused clinical-services model; a $550M vehicle can fund dozens of new doors and the accompanying aesthetician hiring that comes with them. Treatment menus in markets where Peachy expands will likely widen to include injectables, skin-analysis devices and branded post-procedure skincare — adjacent lines Stride's consumer brands can supply.

How a $1.3B shop finds its next deal

Stride's track record leans on category adjacencies: haircare to body care, prestige makeup to prestige skin, clinical skincare to clinical service. The pipeline candidates most likely to surface on Stride's deck include:

• Brands with $10M-$50M in revenue, EBITDA-positive or near-positive
• Founder-led color cosmetics and fragrance houses with creator-economy distribution
• Clinical or derm-adjacent skincare brands ready for a retail step-up
• Multi-unit aesthetic service operators with a membership or membership-like model

Limited partners will press for proof that the first fund's exits — or unrealized marks — clear the 2x hurdle before the new vehicle's deployment window matures. That pressure shapes cadence.

What to watch next

The next data point is not a press release but a deal. Watch for one of two markers in the next two quarters: a bolt-on inside Skinfix or Odele that extends sku count into a new sub-category, or a platform play in professional skincare or aesthetic services that mirrors the Peachy bet. Either would test whether Stride can compound at the unit-economic level its LPs funded on.

Mid-market consumer fundraising has thinned across 2024 and 2025. A clean $550M close at hard cap is the strongest counter-data point yet that beauty — specifically premium, founder-led, clinically positioned beauty — still trades at a premium to dry powder.